Treating steroid-dependent uveitis with combination therapy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate, posterior, or pan-uveitis (inflammation in the middle or back of the eye) that is not caused by an infection.
- In the past 3 months, your uveitis was active despite taking at least 7 mg of prednisone (a steroid) daily.
- You are 18 years or older.
- You are willing to use effective birth control if you or your partner could become pregnant, and continue for 3–5 months after treatment ends.
- You do not have active tuberculosis, untreated latent TB, HIV, hepatitis B or C, or a history of multiple sclerosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study follows adults with non-infectious uveitis (intermediate, posterior, or pan-uveitis) to better understand inflammation activity and treatment needs. It also follows adults having planned eye surgery (like cataract or vitreoretinal surgery) to compare groups.
This trial tests a new cell therapy called TRX103 for people with active uveitis not caused by an infection. It aims to see if the treatment is safe and helps reduce eye inflammation.
This trial tests a different way of giving a steroid injection for eye swelling (macular edema) caused by uveitis. It is for people whose swelling hasn't improved with a standard steroid injection behind the eye.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
Hear when a new Non Infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.